PL2593463T3 - Formulacje ryfaksyminy i ich zastosowania - Google Patents

Formulacje ryfaksyminy i ich zastosowania

Info

Publication number
PL2593463T3
PL2593463T3 PL11807418T PL11807418T PL2593463T3 PL 2593463 T3 PL2593463 T3 PL 2593463T3 PL 11807418 T PL11807418 T PL 11807418T PL 11807418 T PL11807418 T PL 11807418T PL 2593463 T3 PL2593463 T3 PL 2593463T3
Authority
PL
Poland
Prior art keywords
rifaximin
formulations
Prior art date
Application number
PL11807418T
Other languages
English (en)
Inventor
Jon Selbo
Jing TENG
Mohammed A. KABIR
Pam Golden
Original Assignee
Salix Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Salix Pharmaceuticals, Inc. filed Critical Salix Pharmaceuticals, Inc.
Publication of PL2593463T3 publication Critical patent/PL2593463T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1641Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1652Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2027Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4866Organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
PL11807418T 2010-07-12 2011-07-12 Formulacje ryfaksyminy i ich zastosowania PL2593463T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US36360910P 2010-07-12 2010-07-12
US41905610P 2010-12-02 2010-12-02
EP11807418.6A EP2593463B1 (en) 2010-07-12 2011-07-12 Formulations of rifaximin and uses thereof
PCT/US2011/043769 WO2012009388A1 (en) 2010-07-12 2011-07-12 Formulations of rifaximin and uses thereof

Publications (1)

Publication Number Publication Date
PL2593463T3 true PL2593463T3 (pl) 2020-11-02

Family

ID=45469785

Family Applications (1)

Application Number Title Priority Date Filing Date
PL11807418T PL2593463T3 (pl) 2010-07-12 2011-07-12 Formulacje ryfaksyminy i ich zastosowania

Country Status (28)

Country Link
US (4) US20120077835A1 (pl)
EP (2) EP3750526A1 (pl)
JP (1) JP5943915B2 (pl)
KR (1) KR101887004B1 (pl)
CN (1) CN103228662B (pl)
AU (1) AU2011279261B2 (pl)
BR (1) BR112013000802B1 (pl)
CA (1) CA2804635C (pl)
CR (1) CR20130033A (pl)
DK (1) DK2593463T3 (pl)
EA (1) EA033370B1 (pl)
ES (1) ES2801678T3 (pl)
GE (2) GEAP202112996A (pl)
HU (1) HUE049986T2 (pl)
IL (1) IL223725B (pl)
LT (1) LT2593463T (pl)
MX (1) MX345697B (pl)
MY (1) MY165086A (pl)
NZ (1) NZ605232A (pl)
PH (1) PH12013500082B1 (pl)
PL (1) PL2593463T3 (pl)
PT (1) PT2593463T (pl)
SG (2) SG186981A1 (pl)
SI (1) SI2593463T1 (pl)
SM (1) SMT202000390T1 (pl)
TN (1) TN2012000611A1 (pl)
WO (2) WO2012009387A1 (pl)
ZA (1) ZA201300193B (pl)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1698630B1 (en) 2005-03-03 2014-09-03 ALFA WASSERMANN S.p.A. New polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations
ITBO20050123A1 (it) 2005-03-07 2005-06-06 Alfa Wassermann Spa Formulazioni farmaceutiche gastroresistenti contenenti rifaximina
US9018684B2 (en) 2009-11-23 2015-04-28 California Institute Of Technology Chemical sensing and/or measuring devices and methods
IT1398550B1 (it) 2010-03-05 2013-03-01 Alfa Wassermann Spa Formulazioni comprendenti rifaximina utili per ottenere un effetto prolungato nel tempo
ITBO20110461A1 (it) 2011-07-29 2013-01-30 Alfa Wassermann Spa Composizioni farmaceutiche comprendenti rifaximina, processi per la loro preparazione e loro uso nel trattamento di infezioni vaginali.
ES2986825T3 (es) * 2011-11-02 2024-11-12 Salix Pharmaceuticals Inc Rifaximina para la repetición de tratamiento del síndrome del intestino irritable con predominio de diarrea
AU2013212008A1 (en) 2012-01-25 2014-07-10 Alfa Wassermann S.P.A. Rifaximin derivative and uses thereof
ITBO20120368A1 (it) 2012-07-06 2014-01-07 Alfa Wassermann Spa Composizioni comprendenti rifaximina e amminoacidi, cristalli di rifaximina derivanti da tali composizioni e loro uso.
EP2757135B1 (en) 2013-01-18 2017-11-29 3M Innovative Properties Company Method of bonding parts to a vehicle by an acrylic foam tape
WO2015069305A1 (en) * 2013-11-08 2015-05-14 Tyrx, Inc. Antimicrobial compositions and methods for preventing infection in surgical incision sites
CN106795192B (zh) 2014-05-04 2020-06-16 萨利克斯药品公司 Ibs微生物群及其用途
EP3143027B1 (en) 2014-05-12 2019-07-10 Alfasigma S.p.A. New solvated crystal form of rifaximin, production, compositions and uses thereof
EP3307246B1 (en) 2015-06-09 2026-02-18 Lonza Sales AG Formulations to achieve rapid dissolution of drug from spray-dried dispersions in capsules
JP7024248B2 (ja) * 2016-09-01 2022-02-24 大正製薬株式会社 固形製剤
PT3518924T (pt) * 2016-09-30 2022-10-27 Salix Pharmaceuticals Inc Formas de dispersão sólidas de rifaximina
CN110621305A (zh) * 2017-07-24 2019-12-27 爱科思华制药研发有限责任公司 高载药量药物组合物
CN109453165B (zh) * 2018-10-16 2021-02-05 丹诺医药(苏州)有限公司 一种利福霉素-硝基咪唑偶联分子的固体分散体及其应用
CN109453166B (zh) * 2018-10-16 2021-03-12 丹诺医药(苏州)有限公司 一种利福霉素-喹嗪酮偶联分子的固体分散体及其应用
US12357620B2 (en) 2019-03-22 2025-07-15 New York Medical College Use of rifaximin on circulating aged neutrophils in sickle cell disease
WO2021058656A1 (en) 2019-09-24 2021-04-01 Bausch Health Ireland Limited Rifaximin liquid formulations
US20230111568A1 (en) * 2020-03-24 2023-04-13 Bausch Health Ireland Limited Solid dispersions of rifaximin for the treatment of overt hepatic encephalopathy
US20230141118A1 (en) * 2020-04-13 2023-05-11 Bausch Health Ireland Limited Methods of using solid dispersions of rifaximin for the treatment of sickle cell disease
EP4171520A1 (en) 2020-06-26 2023-05-03 Bausch Health Ireland Limited Targeted release rifaximin compositions
WO2022090490A1 (en) 2020-10-29 2022-05-05 Bausch Health Ireland Limited Rifaximin liquid formulations for use in the treatment of sickle cell disease
CN114366717B (zh) * 2022-01-11 2023-06-09 四川农业大学 一种基于egcg纳米粒的肠溶固体分散体颗粒、制备方法及其应用
WO2025151876A1 (en) * 2024-01-11 2025-07-17 Minneamrita Therapeutics Llc Triptolide formulations

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1154655B (it) 1980-05-22 1987-01-21 Alfa Farmaceutici Spa Derivati imidazo-rifamicinici metodi per la loro preparazione e loro uso come sostanza ad azione antibatterica
IT1199374B (it) 1984-05-15 1988-12-30 Alfa Farmaceutici Spa Processo per la preparazione di pirido-imidazo-rifamicine
IT1320176B1 (it) 2000-12-22 2003-11-26 Nicox Sa Dispersioni solide di principi attivi nitrati.
CA2448864C (en) * 2001-06-22 2008-04-22 Pfizer Products Inc. Pharmaceutical compositions containing a solid dispersion of a poorly-soluble drug in a matrix and a solubility-enhancing polymer
ITMI20032144A1 (it) * 2003-11-07 2005-05-08 Alfa Wassermann Spa Forme polimorfe di rifaximina, processi per ottenerle e
EP1701704A2 (en) * 2003-12-31 2006-09-20 Pfizer Products Inc. Solid compositions of low-solubility drugs and poloxamers
MY191349A (en) 2004-08-27 2022-06-17 Bayer Pharmaceuticals Corp New pharmaceutical compositions for the treatment of hyper-proliferative disorders
EP1698630B1 (en) 2005-03-03 2014-09-03 ALFA WASSERMANN S.p.A. New polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations
ITBO20050123A1 (it) * 2005-03-07 2005-06-06 Alfa Wassermann Spa Formulazioni farmaceutiche gastroresistenti contenenti rifaximina
US20080095754A1 (en) * 2006-10-18 2008-04-24 Burke Susan E Ophthalmic compositions comprising diglycine
PT2011486E (pt) * 2007-07-06 2012-08-24 Lupin Ltd Composições farmacêuticas de rifaximina
JP5755878B2 (ja) * 2007-07-06 2015-07-29 ルパン リミテッドLupin Limited リファキシミンの薬剤組成物
KR100903618B1 (ko) * 2007-10-30 2009-06-18 삼성에스디아이 주식회사 플라즈마 디스플레이 패널
US8486956B2 (en) * 2008-02-25 2013-07-16 Salix Pharmaceuticals, Ltd Forms of rifaximin and uses thereof
EP2257557A4 (en) * 2008-02-25 2011-06-29 Salix Pharmaceuticals Ltd FORMS OF RIFAXIMINE AND APPLICATIONS THEREOF
ES2727728T3 (es) * 2008-02-26 2019-10-18 Salix Pharmaceuticals Ltd Métodos para el tratamiento del síndrome del intestino irritable
EP2105130A1 (de) * 2008-03-25 2009-09-30 Ratiopharm GmbH Pharmazeutische Formulierung und Verfahren zu deren Herstellung
KR20110107806A (ko) * 2008-12-10 2011-10-04 시플라 리미티드 리팍시민 복합체
SG10201501054TA (en) * 2009-10-27 2015-04-29 Lupin Ltd Solid dispersion of rifaximin
WO2011061748A1 (en) * 2009-11-19 2011-05-26 Strides Arcolab Limited Rifaximin premix
MY156888A (en) * 2010-03-10 2016-04-15 Abbvie Bahamas Ltd Solid Compositions

Also Published As

Publication number Publication date
EP3750526A1 (en) 2020-12-16
PH12013500082B1 (en) 2019-06-28
MX2013000522A (es) 2013-05-01
KR101887004B1 (ko) 2018-08-09
SG10201505484RA (en) 2015-09-29
WO2012009387A1 (en) 2012-01-19
CA2804635A1 (en) 2012-01-19
PH12013500082A1 (en) 2013-03-11
BR112013000802A2 (pt) 2016-05-24
US9737610B2 (en) 2017-08-22
EP2593463A1 (en) 2013-05-22
LT2593463T (lt) 2020-08-25
JP2013532633A (ja) 2013-08-19
SG186981A1 (en) 2013-02-28
GEAP202112996A (en) 2021-09-10
CA2804635C (en) 2019-09-10
GEP20227342B (en) 2022-01-25
EA201370018A1 (ru) 2013-09-30
KR20130098300A (ko) 2013-09-04
US20170333562A1 (en) 2017-11-23
EP2593463B1 (en) 2020-05-06
EA033370B1 (ru) 2019-10-31
PT2593463T (pt) 2020-09-17
US20120077835A1 (en) 2012-03-29
BR112013000802B1 (pt) 2021-08-31
CR20130033A (es) 2013-04-29
NZ605232A (en) 2015-09-25
EP2593463A4 (en) 2014-04-23
US20150133482A1 (en) 2015-05-14
SI2593463T1 (sl) 2020-10-30
ES2801678T3 (es) 2021-01-12
US20200397904A1 (en) 2020-12-24
WO2012009388A1 (en) 2012-01-19
ZA201300193B (en) 2019-07-31
MX345697B (es) 2017-02-13
AU2011279261A1 (en) 2013-01-17
DK2593463T3 (da) 2020-08-10
IL223725B (en) 2020-03-31
SMT202000390T1 (it) 2020-09-10
CN103228662B (zh) 2016-08-10
TN2012000611A1 (en) 2014-04-01
MY165086A (en) 2018-02-28
HUE049986T2 (hu) 2020-11-30
CN103228662A (zh) 2013-07-31
JP5943915B2 (ja) 2016-07-05
AU2011279261B2 (en) 2016-03-31

Similar Documents

Publication Publication Date Title
ZA201300193B (en) Formulations of rifaximin and uses thereof
ZA201206227B (en) Forms of rifaximin and uses thereof
IL250824B (en) Certain amino-pyrimidines, their assemblies, and methods of using them
ZA201208770B (en) New forms of rifaximin and uses thereof
IL222227A0 (en) Pyrazol - 4 - heterocyclyl-carboxamide compounds and methods of use
ZA201209259B (en) Uses and compositions
GB201006096D0 (en) Novel compositions and uses thereof
EP2563372A4 (en) PREBIOTIC FORMULATIONS AND METHODS OF USE
SI2605757T1 (sl) Formulacije na osnovi nalbufina in njihove uporabe
SI2531518T1 (sl) Oligopeptidne spojine in njihova uporaba
IL227642A0 (en) Rifaximin formulations and their uses
EP2566485A4 (en) IMMUNOSTIMULATORY COMPOSITIONS AND METHODS OF USE THEREOF
ZA201302952B (en) Fungicidal compositions and methods of use
EP2552210A4 (en) FORMULAS FROM MAZINDOL
IL224192A (en) Compositions of Vitamin 14 – Epi Analogs d
IL223269A0 (en) 2 - iminobiotin formulations and uses thereof
HK1185344A (en) Formulations of rifaximin and uses thereof
HK1177104A (en) New forms of rifaximin and uses thereof
HU1000688D0 (en) Use of trifluoro-phal
GB201019291D0 (en) Compositions and uses
GB201020463D0 (en) Herbicidal compositions and methods of use
GB201014319D0 (en) Compounds and uses thereof
HK1177747A (en) Hsa-related compositions and methods of use